Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MicroRNA and mRNA regulatory network in EGFR-mutated lung adenocarcinoma

ABSTRACT: MicroRNA and mRNA regulatory network in EGFR-mutated lung adenocarcinoma

PROVIDER: PRJNA488633 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

MicroRNA and mRNA regulatory network in EGFR-mutated lung adenocarcinoma [miRNA]

Project description:We have examined the both miRNA and mRNA expression profiles in 155 lung adenocarcinoma samples with known EGFR mutation status (52 mutated and 103 wild-type cases). An integrative analysis was performed to identify the unique miRNA-mRNA regulatory network in EGFR-mutated lung adenocarcinoma.

2018-11-13 | GSE119268 | GEO

MicroRNA and mRNA regulatory network in EGFR-mutated lung adenocarcinoma [mRNA]

2018-11-13 | GSE119267 | GEO

MicroRNA and mRNA regulatory network in EGFR-mutated lung adenocarcinoma [miRNA]

Project description:MicroRNA and mRNA regulatory network in EGFR-mutated lung adenocarcinoma [miRNA]

| PRJNA488634 | ENA

MicroRNA and mRNA regulatory network in EGFR-mutated lung adenocarcinoma [mRNA]

Project description:MicroRNA and mRNA regulatory network in EGFR-mutated lung adenocarcinoma [mRNA]

| PRJNA488635 | ENA

Small RNA sequencing of primary EGFR-mutated lung adenocarcinoma tissues from patients with postoperative recurrence

Project description:Small RNA sequencing was performed to identify dysregulated microRNAs associated with postoperative recurrence of EGFR-mutated lung adenocarcinoma. Five primary EGFR-mutated lung adenocarcinoma tissues from patients who later developed recurrence and five normal lung tissues were analyzed.

2026-08-05 | GSE330633 | GEO

Unique microRNA profiles in EGFR-mutated lung adenocarcinomas

Project description:We have examined the microRNA expression in 154 lung adenocarcinoma samples and 20 paired normal lung tissue samples and investigated the microRNA expression to clinical variables, EGFR- and KRAS- mutational status and time to progression. 174 samples are analyzed. 154 from lung adenocarcinoma tumor tissue and 20 from paired normal lung tissue samples. No replicates or control samples included.

2014-03-10 | E-GEOD-48414 | biostudies-arrayexpress

Unique microRNA profiles in EGFR-mutated lung adenocarcinomas

2014-03-10 | GSE48414 | GEO

Expression Profiling of MicroRNAs in Relation to EGFR Mutation status in Japanese Smoker Male with Lung Adenocarcinoma [blood plasma]

Project description:The lung adenocarcinoma has an increased incidence in smokers. The molecular target therapy has been developed for lung adenocarcinoma patients harboring EGFR gene mutation. However, the treatment options for the patients without mutation are currently limited. Thus, analysis of EGFR gene mutation status at early stage is important strategy to classify patients for effective treatments and improving prognosis. This study aimed to identify microRNA (miRNAs) signature in relation to mutation status in EGFR gene in early stage of lung adenocarcinoma male patients with smoking history. MiRNA profiles were assessed by microarray in paired plasma and tissue pooled from 10 EGFR wild type (EGFR-wt) and 10 EGFR mutated (EGFR-mut) patients.

2018-02-14 | GSE102222 | GEO

Expression Profiling of MicroRNAs in Relation to EGFR Mutation status in Japanese Smoker Male with Lung Adenocarcinoma [adinocarcinoma tissue]

2018-02-14 | GSE102223 | GEO

CCL20 Released by Drug-Tolerant Persisters Impairs Immunotherapy in EGFR-Mutated Lung Adenocarcinoma

Project description:EGFR-mutated lung adenocarcinoma (LUAD) often shows suboptimal response to immune checkpoint inhibitors (ICIs), attributed to an immunosuppressive tumor immune microenvironment (TIME). Drug-tolerant persisters (DTPs), a subpopulation of cancer cells that can survive initial therapy, contribute to this resistance by releasing CCL20, a chemokine that fosters tumor immune privilege. This preclinical study aims to explore the role of CCL20 in modulating TIME and its impact on ICI efficacy in EGFR-mutated LUAD. We utilized a humanized mouse model engrafted with EGFR-mutated NCI-H1975 LUAD cells and human peripheral blood mononuclear cells (PBMCs) to mimic a human immune system. Mice were treated with anti-PD-1, anti-CCL20, or a combination of both. Xenograft growth was monitored, and resected xenograft were analyzed using single-cell RNA sequencing (scRNA-seq) and multiplex immunofluorescence microscopy to assess changes in tumor cell transcriptional profiles and immune cell infiltration including. Results demonstrated that anti-PD-1 or anti-CCL20 monotherapy showed minimal effects on tumor growth, their combination significantly suppressed tumor progression and CCL20 expression in DTP subpopulations and altered the transcriptional profile of tumor cells. Combined treatment also reduced hypoxia-related genes and appeared to enhance stress response pathways. In addition, the combined treatment enhanced infiltration of immune cells, shifting the TIME toward an immunogenic state. In conclusion, co-inhibition of CCL20 and PD-1 remodels the TIME, overcoming ICI resistance in EGFR-mutated LUAD. These findings suggest that targeting CCL20 alongside PD-1 blockade could enhance immunotherapy efficacy, offering a novel therapeutic strategy for this patient population.

2026-08-12 | GSE293914 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data